Andrographolide Inhibits Static Mechanical Pressure-Induced Intervertebral Disc Degeneration via the MAPK/Nrf2/HO-1 Pathway

Drug Des Devel Ther. 2023 Feb 20:17:535-550. doi: 10.2147/DDDT.S392535. eCollection 2023.

Abstract

Purpose: To explore the molecular mechanism by which andrographolide (ADR) inhibits static mechanical pressure-induced apoptosis in nucleus pulposus cells (NPCs) and to assess the role of ADR in inhibiting IDD.

Methods: Hematoxylin-eosin (HE), toluidine blue, and immunofluorescence staining were used to identify NPCs. An NPC apoptosis model was constructed using a homemade cell pressurization device. The proliferation activity, reactive oxygen species (ROS) content, and apoptosis rate were detected using kits. The expression of related proteins was detected using Western blot. A rat tailbone IDD model was constructed using a homemade tailbone stress device. HE staining and safranine O-fast green FCF cartilage staining were used to observe the degeneration degree of the intervertebral disk.

Results: ADR inhibits static mechanical pressure-induced apoptosis and ROS accumulation in NPCs and improves cell viability. ADR can promote the expression of Heme oxygenase-1 (HO-1), p-Nrf2, p-p38, p-Erk1/2, p-JNK, and other proteins, and its effects can be blocked by inhibitors of the above proteins.

Conclusion: ADR can inhibit IDD by activating the MAPK/Nrf2/HO-1 signaling pathway and suppressing static mechanical pressure-induced ROS accumulation in the NPCs.

Keywords: HO-1; andrographolide; apoptosis; intervertebral disc degeneration; nucleus pulposus cells; reactive oxygen species.

MeSH terms

  • Animals
  • Apoptosis
  • Intervertebral Disc Degeneration* / drug therapy
  • Intervertebral Disc Degeneration* / metabolism
  • MAP Kinase Signaling System
  • NF-E2-Related Factor 2 / metabolism
  • Rats
  • Reactive Oxygen Species / metabolism
  • Signal Transduction

Substances

  • andrographolide
  • NF-E2-Related Factor 2
  • Reactive Oxygen Species
  • Hmox1 protein, rat

Grants and funding

This research was funded by Jining City Key Research and Development Program Project, grant number 2020JKNS008, and Shandong Province Medical and Health Science and Technology Development Plan Project, grant number 202104070383.